Full Papers
Validation of the Spanish version of the fibromyalgia rapid screening tool to detect fibromyalgia in primary care health centres
B. Casanueva1, R. Belenguer2, J.V. Moreno-Muelas3, J. Urtiaga4, B. Urtiaga5, J.L. Hernández6, T. Pina7, M.A. González-Gay8
- Rheumatology, Clínica de Especialidades Cantabria, IDIVAL, Santander, Spain.
- Rheumatology, Hospital 9 de Octubre, Valencia, Spain.
- Rheumatology, Hospital Vall D’Hebron, Barcelona, Spain.
- Professor of French Language, Madrid, Spain.
- Professor of Spanish Language and Literature, Madrid, Spain.
- Division of Internal Medicine, Hospital Universitario Marqués de Valdecilla, RETICEF, IDIVAL, Santander, Spain.
- Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.
- Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain. miguelaggay@hotmail.com
CER9134
2016 Vol.34, N°2 ,Suppl.96
PI 0125, PF 0128
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 27055283 [PubMed]
Received: 21/11/2015
Accepted : 15/02/2016
In Press: 07/04/2016
Published: 06/05/2016
Abstract
OBJECTIVES:
To investigate the reliability and validity of the Spanish version of the Fibromyalgia Rapid Screening Tool (FiRST), a brief questionnaire for the detection of fibromyalgia (FM) in patients with diffuse chronic pain seen at primary care health centres.
METHODS:
The original FiRST French questionnaire was adapted to a Spanish version following the guidelines of the Rheumatology Spanish Society Study Group of FM, and the help provided by professors of French and Spanish Language. In a prospective and multicentre study, patients with chronic pain were initially divided into two groups: a group that included patients that had been diagnosed with FM according to the 1990 ACR criteria and the 2010 ACR preliminary criteria (n=404), and a non-FM (control) group composed of rheumatoid arthritis (RA) (n=147) and osteoarthritis (OA) (n=219) patients. Patients from the FM group were evaluated by assessing tender point assessment, Widespread Pain Index (WPI), Symptom Severity Scale (SSS), FiRST questionnaire and Fibromyalgia Impact Questionnaire (FIQ). The non-FM group was evaluated by means of FiRST, WPI and SSS. Sensitivity, specificity and predictive value as well as the correlation between the global score and other parameters were assessed.
RESULTS:
356 of 404 FM (88.1%) patients who met the 1990 ACR criteria and the ACR 2010 preliminary criteria had a positive FiRST. In the control group (AR plus OA), only 16 (4.4%) subjects had a positive FiRST. The sensitivity value was 92% (95% confidence interval CI: 88.9-95.1), specificity 87.4% (95% CI: 80.8-94.0), positive predictive value 95.7% (95% CI: 93.3-98.1), and negative predictive value 78.2% (95% CI: 70.6-85.9). A significant correlation between the total FiRST score (patients with score 5 or 6) and WPI (p<0.0001), SSS (p<0.0001), time to disease progression (p<0.0001) and FIQ (p<0.0001) was found.
CONCLUSIONS:
FiRST questionnaire is a useful tool for the detection of FM in primary care health centres.